Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
Silvio E. Inzucchi, Brian Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Mikhail Kosiborod, Carolyn S.P. Lam, Felipe A. Martínez, Sanjiv J. Shah, Subodh Verma, Yaling Han, José Francisco Kerr Saraiva, Olof Bengtsson, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon
Topics & Concepts
MedicineHeart failureEjection fractionDapagliflozinInternal medicineAtrial fibrillationPlaceboCardiologyPrediabetesType 2 diabetesAdverse effectDiabetes mellitusEndocrinologyAlternative medicinePathologyDiabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patientsCardiovascular Function and Risk Factors